Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2011. The report details a specific share repurchase transaction executed on October 18, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 300,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,372 pence per share; lowest price paid was 1,364.5 pence per share.
- Treasury Holdings (Settled): 507,146,370 shares (9.10% of total issued share capital).
- Treasury Holdings (Including Unsettled): 507,971,370 shares (10.03% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,063,144,116 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 300,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury to 10.03% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (507,146,370 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (5,063,144,116 shares in issue) for disclosure threshold assessments.
- Review the remaining authority under the May 5, 2011 shareholder mandate for future repurchases.